# TRAINING UPDATE

Lab Location: Department: GEC, SGAH & WAH QA & Mgmt

 Date Distributed:
 3/19/2015

 Due Date:
 3/31/2015

 Implementation:
 4/1/2015

# **DESCRIPTION OF PROCEDURE REVISION**

Name of procedure:

# Proficiency Test Results Evaluation GEC / SGAH / WAH.QA21v3

**Description of change(s):** 

	add SD and SDI, remove dry erase board add email of failures, update near miss evaluation and ungraded challenge criteria, add online continuing education	
Section 9:	remove near miss flow chart	
An examj SOP	ple of the near miss documentation is attached after the	
This revised SOP will be implemented on April 1, 2015		

Document your compliance with this training update by taking the quiz in the MTS system.

### Non-Technical SOP

Title	Proficiency Test Results Evaluation	
Prepared by	Leslie Barrett	Date: 12/29/2009
Owner	Cynthia Bowman-Gholston	Date: 12/29/2009

Laboratory Approval		
Print Name and Title	Signature	Date
<i>Refer to the electronic signature page for approval and approval dates.</i>		
Local Issue Date:	Local Effective Date:	

Review:		
Print Name	Signature	Date

# TABLE OF CONTENTS

1.	PURPOSE	. 2
2.	SCOPE	. 2
3.	RESPONSIBILITY	. 2
4.	DEFINITIONS	. 3
5.	PROCEDURE	. 3
6.	RELATED DOCUMENTS	. 8
7.	REFERENCES	. 8
8.	REVISION HISTORY	. 9
9.	ADDENDA AND APPENDICES	. 9

# 1. PURPOSE

Proficiency testing results are used to:

- Determine the quality of the laboratory performance
- Compare performance with peer groups
- Utilize the results as an educational and evaluative tool for employees and/or instrument/reagent performance.

## 2. SCOPE

All clinical laboratory staff involved in specimen testing are required to participate in proficiency testing.

## 3. **RESPONSIBILITY**

## A. Laboratory Medical Director

Provides final review of all aspects of proficiency testing (PT) in Clinical Laboratory departments.

**B.** Laboratory Operations Director

Review of PT results and any required follow-up

## C. Technical Supervisors

Provide primary review and evaluation of PT results received with investigation and corrective action, as necessary.

**D. Quality Assurance staff** Track routing of results to verify timely completion and thoroughness of investigation.

## **E.** Staff technologists and technicians Review PT evaluation as a mechanism for continuing education.

Form revised 3/31/00

# 4. **DEFINITIONS**

**Proficiency Testing (PT)** – A means to determine that test methods are performing as expected through outcomes for predetermined standards.

CAP – College of American Pathologists

LAP – Laboratory Accreditation Program of CAP

**CAP PT database** – Excel spreadsheet utilized to track all aspects of Proficiency Testing materials including:

- A. Applicable survey descriptions and codes
- **B.** Ship date
- C. Receipt date
- **D.** Due date for results to be submitted
- E. Actual date results are submitted
- F. Date CAP evaluation of results is received
- G. Date final signed report is returned for filing

**Survey Error Investigation and Corrective Action Report (SEICAR)** – a form used to document the investigation and corrective actions taken to proficiency testing non-conformances

**Graded Result** – a result that the proficiency agency has formally evaluated for acceptability against a peer group or all method results using defined evaluation criteria

**Near-miss** – a graded result that was close to non-conformance ( $\pm 2.5$  SDI or greater) but did not actually exceed the proficiency agency's acceptance criteria. Near misses must be investigated to evaluate future risk and to correct existing problems before an actual non-conformance occurs.

**Ungraded Result** – a result that the proficiency agency has not formally evaluated for acceptability (e.g., lack of participant consensus, peer groups that are too small for statistical evaluation, results reported using '<' or '>', and educational challenges).

**Standard Deviation (SD)** – a measurement of the dispersion of data around the mean. The SD decreases as variation decreases.

**Standard Deviation Index (SDI)** – a statistical tool that describes how far a single proficiency testing result is from the target value (in SDs).

# 5. **PROCEDURE**

## A. Result Communication Prohibition

• Intra- or inter-laboratory communication regarding PT materials or results is prohibited until the PT provider has formally evaluated the results. (Questions regarding the administration of the PT program or material

Form revised

. 3/31/00

integrity may be directed to the Laboratory Director, designee, or PT provider, but communications or discussions concerning PT results are prohibited.)

• Refer to the QA procedure 'Procedure for handling Inappropriate Referral or Proficiency Materials or Inter/Intra laboratory Communication of Proficiency Test Information' for additional details.

# B. Routing of Results/Evaluation

Step	Action	
1	The College of American Pathologists (CAP) responds to survey input by supplying a critique and summary report of all method groups. This information is mailed to the facility and may be accessed on the CAP website. An email notice is	
	<ul> <li>also sent to the CLIA site CAP administrators when website results are published.</li> <li>The QA specialist or designee will view the evaluation and assess for failures and near misses.</li> </ul>	
	<ul> <li>No action is required if all results are acceptable.</li> <li>If there are unacceptable results (failure or near-miss), the evaluation is emailed to the Technical Supervisor to begin the investigation. Refer to sections E, F and H as applicable.</li> </ul>	
2	The <b>Technical Supervisor, QA specialist or designee</b> will route the results and critique to Laboratory leadership (Technical Supervisor, Medical Director, Laboratory Operations Director – see Responsibility section).	
3	Results will be reviewed and evaluated as <b>expeditiously</b> as possible (within two weeks). Proficiency testing results must be signed by the Technical	
	Supervisor/Manager, Medical Director, Operations Director or designee(s), and the QA specialist or designee.	
4	The supervisor will document the investigation of any unsatisfactory PT results or results that do not agree with the majority of respondents on a Survey Error Investigation and Corrective Action Report. (Refer to section E)	
5	Corporate Medical Quality also requires that any result deemed "near miss", must be investigated.	
	• Graded results that meet the PT provider's acceptance criteria are evaluated internally to detect "near-misses" for each analyte. Near-misses are opportunities to detect and correct problems before an actual miss occurs. Near-misses are not counted as PT non-conformances.	
	• If a near-miss is detected, the investigation/corrective actions (if required) must be documented.	
	• PT results are initially assessed visually, using SDIs, charts or other tools provided on the PT report. It is not necessary to perform near-miss calculations for every PT challenge, just the challenges that visually appear to meet the near-miss criteria.	
	• Refer to Section F for investigation and documentation process.	

_		
	6	Refer to Section H if a challenge is ungraded due to one of the following:
	0	A. Routinely ungraded analyte/result
		B. Educational challenge
		C. Lack of participant consensus
		D. Results submitted after cut-off date
		E. Results not submitted
		F. Appropriate method code was not submitted
	7	All documentation is returned to QA staff for filing and database input

# C. Staff Feedback/Continuing Education

Step	Action
1	PT materials consisting of photomicrographs are reviewed by the Medical Director and used as a Continuing Education resource.
2	The Analyte Scorecard on the CAP website will be posted quarterly for staff.
3	Continuing education credits are available online from CAP for selected surveys. This information is communicated to staff via the Sunquest Mailbox function and posted in each lab, including site-specific CAP numbers, kit numbers and the expiration dates for acquiring credit. Participation is voluntary.

# **D. Proficiency Testing Exception Summary (PTES)**

Step	Action
1	A Proficiency Testing Exception Summary (PTES) is issued by CAP if the
1	performance of an analyte falls below the LAP's acceptable criteria for PT.
2	This report is designed to ensure the monitoring of PT performance for purposes of
2	CAP and CLIA certification. PTES notification will be issued for regulated
	analytes (analytes that CLIA requires PT) that are reported to the Centers for
	Medicaid Medicare Standards (CMS), regulated analytes that are not reported to
	CMS; and non-regulated analytes.
3	CAP mails the PTES reports to the Medical Director, who delivers them to the
5	appropriate supervisor for tracking. The PTES packet includes instructions for
	responding to the PT exception, an exception response form, and a summary of
	scores for the previous four PT testing events.

# E. Survey Error Investigation and Corrective Action Report (SEICAR)

Step	Action		
1	The process for investigation of PT failures is defined and includes the following analysis:		
	•	Assess what went wrong. Is there a problem?	
	•	How did we identify the problem or exclude it?	
	•	Outline steps followed during investigation. QC review, patient data, technolo performance, etc.	
	•	What steps will be taken to prevent a recurrence?	

Form revised 3/31/00

	Was patient care affected?
	The process applies to each analyte missed (graded or ungraded). The flowcharts
	in Addenda B may be utilized to assist in the investigation process.
	A Survey Error Investigation and Corrective Action Report form is required to
2	document and code this process.
	The technical supervisor or designee will:
3	
	• Lead the investigation process.
	• Interview involved staff members.
	• Review all records associated with the batch(es) that contained the
	proficiency testing specimen(s). These records include but are not limited
	to: test records, worksheets, instrument preventive maintenance records,
	calibration records (instruments, pipettes, centrifuge, etc.),
	daily/weekly/monthly QC records, the Survey Companion Form, the
	proficiency survey result reporting form, participant summary, and previous
	PT results.
	• Request retesting the sample, if it's available and document the results on
	the SEICAR. The proficiency agency may be contacted to obtain additional
	specimen for evaluation (additional fee may apply). Document on the
	SEICAR if no specimen is available for retesting.
	Note: In the case of an event failure, the evaluation must include a
	mechanism to demonstrate the test is currently performing acceptably
	• List all issues identified during the record review on the SEICAR in the area
	entitled "Review of Testing Records." Determine if any of the listed issues
	caused or contributed to the proficiency miss or near-miss. From this
	information, and using the Survey Error Investigation Flow Charts
	(Addendum B), assign an error code (Addendum A) to the non-
	conformance.
	• Determine the root cause of the non-conformance.
	• Determine if the PT miss(es) could have any impact on patient samples
	tested before, during or after the failed PT event.
	• Define the required corrective action(s) taken to correct the problem and
	record this information on the SEICAR. The corrective actions must
	include effective date(s).
	• Define what steps/actions are required to prevent recurrence of this non-
	conformance.
	• Define what monitoring steps/actions may be required to ensure the
	corrective action is maintained over time.
	• Draft the SEICAR within 5 working days. The completed form, CAP
	evaluation report and any accompanying letters and documentation will be
	given to the Medical Director and Operations Director for review, approval
	and signature.
	<ul> <li>If approved by the Medical Director and Operations Director the report will</li> </ul>
	then be signed by the Technical Supervisor. If the report is not approved,
	the supervisor will make appropriate revisions and return to the Medical and
	Operations Directors for review and approval.
	• Completed documentation is returned to Hospital QA staff for signature and
	filing.

4	Hospital QA staff will retain a copy of the signed SEICAR with the CAP PT results
	and submit the completed, signed report to Baltimore QA. Refer to Section I for
	additional details.

# F. Near Miss Investigation

Step	Action
1	The process for investigation of a near miss includes
1	• Evaluation of testing vs. submitted result
	• Evaluation of QC
	• Repeat sample testing, if applicable
	• Previous survey failures, if applicable
	• Assessment of the review
	• If errors are detected, complete a SEICAR including root cause and
	corrective action documentation.
2	The investigation is documented on the CAP summary report. All documentation is
2	reviewed by the Operations Director and Medical Director. SEICAR is also
	completed if errors are detected.

# G. Maryland Department of Health

Step	Action
1	A letter may also be received from the Maryland Department of Health requesting
1	documentation/explanation of a proficiency testing failure.
2	The same process, corrective action form, and response will be supplied to the State
2	of Maryland.
3	Written responses are submitted to the Operations Director and the Medical
5	Director for review and signature.
4	Responses are sent to the State of Maryland via certified return receipt requested,
-	US mail. Copy all correspondence to the Baltimore QA department.
5	A copy of the response letter is attached to the proficiency testing results and filed
5	in the appropriate survey notebook. The certified mail receipt is attached to the
	letter.

# H. Ungraded Challenges

Step	Action
1	The QA specialist or Technical supervisor will review the laboratory's result(s) and compare with those provided in the CAP critique or explanation booklet. The
	following criteria is utilized:
	Quantitative: For Peer Group Mean: $\pm 3$ SDI
	Near Miss: $\pm 2.5$ SDI
	For All Method Mean: $\pm 3$ SDI
	Near Miss: $\pm 2.5$ SDI

	Semi-Quantitative: Six or fewer possible categories: Most frequent response ± 1 category More than six possible categories: Most frequent response ± 2 categories								
	Qualitative: Agreement with majority response (>50% consensus) of peer group, all methods, or referee group								
	If the above standards cannot be applied, the Laboratory Director or designee version evaluate the results using clinical judgment, medical usefulness, or equivalency Results of this alternative evaluation must be explained in writing.								
2	The QA specialist or Technical supervisor will document the review and include an assessment of acceptability.								
	• For results deemed unacceptable, a SEICAR will be completed following the steps outlined in Section E.								
	• For near miss results, refer to Section F. All documentation is reviewed by the Operations Director and Medical Director.								

## I. Records

Step	Action
1	A result summary is maintained in an Excel spreadsheet. The QA staff logs the
-	date results are received and the date the final reports are returned for filing.
2	Completed and signed SEICARs are electronically scanned, saved and hyperlinked
2	to the PT Nonconformance database. The report is saved on the G-drive using the
	following pathway:
	G:\CHYDept\AHC_Lab\Quality Assurance\Proficiency Testing\Problem
	Reports_pdf files
3	All survey documentation maintained for the duration outlined in the Quest
5	Diagnostics Record Retention Policy.

# 6. **RELATED DOCUMENTS**

- Proficiency Test Handling and Result Submission, QA procedure
- Procedure for handling Inappropriate Referral or Proficiency Materials or Inter/Intra laboratory Communication of Proficiency Test Information, QA procedure
- Internal Proficiency Testing Policy, QA procedure
- Retention of Records and Materials, Laboratory policy
- Survey Error Investigation and Corrective Action Report (AG.F285)

# 7. **REFERENCES**

- Commission on Laboratory Accreditation Inspection Checklist, Laboratory General, Proficiency Testing section, College of American Pathologists, 325 Waukegan Road, Northfield, Illinois, 60093-2750.
- College of American Pathologists website, <u>www.cap.org</u>
- Quest Diagnostics Process for Evaluation of Proficiency Test Results, QDNQA716

Form revised 3/31/00

# 8. **REVISION HISTORY**

Version	Date	Reason for Revision	Revised By	Approved By
		Supersedes SOP QA002.003		
000	5/7/2012	Section 5: B.3 & H.29 revised to match practice;	L Barrett	C Bowman
		C.9 revised to post CAP Analyte Scorecard		
		Section 9: Update appendix A and addenda B&C		
001	4/18/2014	Section 4: add SEICAR, graded / ungraded results,	L Barrett	C Bowman
		near miss		
		Section 5: update near miss and ungraded criteria;		
		remove CLIA detail; add detail for SEICAR		
		process; replace Chantilly with Baltimore QA		
		Section 6: add updated SEICAR form		
		Section 9: update addenda A&B, add C&D		
		Footer: version # leading zero's dropped due to new		
		EDCS in use as of $10/7/13$ .		
2	3/2/2015	Section 4: add SD and SDI, remove dry erase board	L Barrett	C Bowman
		Section 5: add email of failures, update near miss	R SanLuis	
		evaluation and ungraded challenge criteria, add		
		online continuing education		
		Section 9: remove near miss flow chart		

# 9. ADDENDA AND APPENDICES

- A. Survey Nonconformance Error Codes
- B. Proficiency Testing Result Evaluation Flowchart
- C. Approved Proficiency Testing Agencies


# Addendum A

Audendum A	Survey Non-conformance Error Key	
Error Category	Error Description	Error Code
Method Issues	Survey agency uses 'all methods mean' to grade our results. Our method has bias to agency criteria used.	M-1
	Survey specimen beyond method linearity (either low or high).	M-5
	Method used lacks precision (at least 3 sigma).	M-6
	Sensitivity inadequate for the survey.	M-7
Reagent Issues	Reagent used deteriorated due to either improper storage or deterioration near expiration date (e.g. based on shift in QC not observed at time of testing).	R-1
	Assay bias caused by specific lot of reagent.	R-2
	Reagent improperly stored (temperature, light sensitivity, etc.).	R-3
Quality Control Issues	QC material used deteriorated due to either improper storage or deterioration near expiration date.	Q-1
	Established QC range does not properly control the assay.	Q-2
Calibration Issues	Standard/Calibrator used deteriorated due to either improper storage or deterioration near expiration date.	C-1
100000	Calibration not performed correctly (e.g., incorrect frequency, factors, set points, etc.).	C-2
	Bias attributed to Calibration.	C-3
Instrument Issues	Instrument linearity problem.	I-1
	Instrument sensitivity problem.	I-2
	Instrument specificity/interference problem.	I-3
	Carryover from previous specimen (carryover issue with instrument not identified during original validation).	I-4
	Instrument part(s) failed during survey specimen analysis.	I-5
	Instrument maintenance was not performed at the required interval(s).	I-6
	Required maintenance frequency not adequate for volume on instrument.	I-7
	Instrument/method environment issues (humidity, temperature, sunlight, etc.).	I-8
Technologist Issue	The technologist did not follow the Quest Diagnostics testing procedure. (use T-14 if the survey agency instructions for testing were not followed)	T-1
	Survey specimen(s) mishandled prior to testing (not reconstituted according to agency instructions, survey specimen(s) not adequately mixed, mislabeled, or contaminated).	T-2
	Pipetting error made during the test process (wrong type of pipette used, wrong volume used, etc.)	T-3

Error Description	Error Code
Manual calculations not performed as directed in SOP (includes	T-5
failure to correct for dilution or wrong factor used).	
Wrong dilution performed.	T-6
Delay in testing (time between reconstitution or opening of	T-7
survey specimen and performance of test).	
Technologist assayed wrong survey specimen for required test	T-9
	T-10
	T-11
slide.	
Technologist misinterpreted reaction or data.	T-12
<u> </u>	T-13
	T-14
Survey agency instructions for speciment testing not followed.	1 1 1
Results entered incorrectly on-line or onto the survey result	NT-1
	NT-2
	NT-3
	NT-4
	141-4
	NT-5
	111 5
	NT-7
	111-7
were not sent of faxed to agency.	
Survey specimen was compromised prior to receipt by	SS-2
	55 2
· · · · · · · · · · · · · · · · · · ·	SS-3
, <u>, , , , , , , , , , , , , , , , , , </u>	SS-4
Survey specificit matrix issue.	+-66
Survey agency does not have peer group for method used	SA-3
	SA-5
	SA-4
Data entry erfor made by the agency.	5A-4
After thorough review of testing records (OC Instrument PM	Е
	L
	F
section.	г
	Manual calculations not performed as directed in SOP (includes failure to correct for dilution or wrong factor used). Wrong dilution performed. Delay in testing (time between reconstitution or opening of survey specimen and performance of test). Technologist assayed wrong survey specimen for required test (includes sequence problems). Batch containing survey specimen(s) had significant bias (shift and/or trend) that was not identified. Technologist misidentified cell/organism on photomicrograph or

CONFIDENTIAL: Authorized for internal use only. Page 11 of 22 Quest Diagnostics Site: Germantown Emergency Center


Addendum B






CONFIDENTIAL: Authorized for internal use only. Page 12 of 22 Title: Proficiency Test Results Evaluation

#### Addendum B (continued)



Quest Diagnostics Site: Germantown Emergency Center


Addendum B (continued)






Title: Proficiency Test Results Evaluation

#### Addendum B (continued)




Quest Diagnostics Site: Germantown Emergency Center

Addendum B (continued)







#### Addendum B (continued)



SOP ID: GEC.QA21 SOP version # 3

CONFIDENTIAL: Authorized for internal use only. Page 17 of 22







Quest Diagnostics Site: Germantown Emergency Center

Page 20 of 22

Addendum B (continued)

SOP version # 3






SOP ID: GEC.QA21 SOP version # 3

CONFIDENTIAL: Authorized for internal use only.

Page 19 of 22

F, Other – Find detailed investigation findings in the Comments section.



Addendum C

### **External Proficiency Programs**

#### Approved for Accuracy Evaluations by Alternative Performance Assessment

Agency	Telephone Number
College of American Pathologists (CAP)	(800) 323-4040
Accutest, Inc.	(800) 665-2575
American Association of Bioanalysts (AAB)	(800) 234-5315
American Proficiency Institute (API)	(800)333-0958
New York State Department of Health	(518) 474-8739
Puerto Rico Proficiency Testing Service	(787) 274-6827
WSLH	(800) 462-5261

### **Other CLIA Approved Proficiency Programs**

Agency	Telephone Number
American Academy of Family Physicians (AAFP)	(800) 274-7911
California Thoracic Society (CTS)	(714) 730-1944
Medical Laboratory Evaluation Program (MLE)	(800) 338-2746
Commonwealth of Pennsylvania	(610) 280-3464

SOP ID: GEC.QA21 SOP version # 3

CONFIDENTIAL: Authorized for internal use only. Page 21 of 22 SOP ID: GEC.QA21 SOP version # 3 CONFIDENTIAL: Authorized for internal use only. Page 22 of 22



**College of American Pathologists** 325 Waukegan Road, Northfield, Illinois 60093-2750 800-323-4040 • http://www.cap.org

Advancing Excellence

# ORIGINAL EVALUATION

		AL2-A	2014 Alcohol/Ethylene Gl	lycol/Volatiles	
INSTITUTION: ATTENTION:	Shady Grove Adventist Germantown MD 20874 Cynthia Bowman-Ghols	4-1221			
	-				
CAP NUMBER:	7196153-01	Kit# 1			
KIT INFORMATION:	Kit ID: 26431235	Kit Mailed: 3/3/2014	Original Evaluation: 4/3/2014		Next Mailing Date: 6/2/2014
COPIED TO:	Turner, Janet B CQA(A CMS (21D1057352)	SQ)	Quest Diagnostics-Electronic PT	LAP	
LEGEND:	Exception Reason Cod <none></none>	des appearing in this e	valuation:		
		Reviewed By		Date	

The College of American Pathologists recommends that the result of this interlaboratory comparison not be used as a sole criterion for judging the performance of any individual clinical laboratory.

AL2-A 2014 Alcohol/Ethylene Glycol/Volatiles         ORIGINAL         Test       Vour       No. of       Limits of Acceptability       Your       Plot of the Relative Distance of Your Results         Test       Your       No. of       Limits of Acceptability       Your         Peer Group       Plot of the Relative Distance of Your Results         Specimen       Result       Mean       S.D.       Lower       Upper       Plot of the Relative Distance of Your Results         Specimen       Result       Mean       S.D.       Lower       Upper       Plot of the Relative Distance of Your Results         Specimen       Result       Mean       S.D.       Lower       Upper       Plot of the Relative Distance of Your Results         Survey       -100	College of American Pathologists 325 Waukegan Road, Northfield, Illinois 60093-2750 800-323-4040 • http://www.cap.org Advancing Excellence			CAP Number: 7196153-01 Kit# 1 Institution: Shady Grove Adventist Emergency Ctr Lab Attention: Cynthia Bowman-Gholston MT(ASCP) City / State: Germantown MD 20874-1221				ergency Ctr MT(ASCP	Kit ID: 26431235 Kit Mailed: 3/3/2014 Original Evaluation: 4/3/2014			
Unit of Measure Peer Group         Your Specimen         No. of Result Mean         Limits of Acceptability S.D.         Your Limits of Acceptability         Your Grade         Target as Percentages of allowed Devia           Sthanol         AL2-01         \$8.00         \$0.585         2.294         2608         +3.2         37.93         63.24         Acceptable         AL2-02         88.00         \$1.016         2.2.97         2608         +3.2         37.93         63.24         Acceptable         AL2-02         AL2-03         261.00         253.882         7.778         2008         +0.9         190.41         317.36         Acceptable         AL2-03         AL2-04         122.00         100.354         3.490         2615         +0.5         75.26         125.45         Acceptable         AL2-03         Acceptable         AL2-03         Acceptable         AL2-04         Al2-00         100.354         3.490         2615         +0.5         75.26         125.45         Acceptable         Acceptable         Al2-04         Al2-04 <th colspan="4"></th> <th></th> <th></th> <th>1</th> <th>AL2-A</th> <th><b>2014</b></th> <th>Alcohol/</th> <th>Ethylene</th> <th>Glycol/Volatiles</th>							1	AL2-A	<b>2014</b>	Alcohol/	Ethylene	Glycol/Volatiles
mg/dL       AL2-02       88.00       81.016       2.987       261.4       +2.3       60.76       101.28       Acceptable       AL2-024       AL2-03       261.00       253.882       7.778       2608       +0.9       190.41       317.36       Acceptable       AL2-024       AL2-03       122.00       122.00       120.068       4.063       2610       +5.5       90.05       150.09       Acceptable       AL2-024       AL2-03       102.00       100.354       3.490       2615       +0.5       75.26       125.45       Acceptable       AL2-03       AL2-04       -0.0	Unit of Measure	Spe	ecimen		our		No. of	Ι	Limits of A	-		Plot of the Relative Distance of Your Results from Target as Percentages of allowed Deviation           Survey         -100Mean+100
Yes       No       N/A       Comments         Clerical error	mg/dL	AL V AL AL	.2-02 .2-03 .2-04	8 26 12	38.0081.01631.00253.88222.00120.068	2.987 7.778 4.063	2614 2608 2610	+2.3 +0.9 +0.5	60.76 190.41 90.05	101.28 317.36 150.09	Acceptable Acceptable Acceptable	AL2-C 2013
Clerical error I   Previous failures I   Instrument Review: I   Calibration OK I	Near Miss Evaluation	Spec	cimen:			Analyte				-91		
Previous failures  Previous failures Previous fa		Yes	No	N/A	Commen	ts						
Testing repeated	Clerical error											
QC Review:   Any bias or trends   Peer comparison OK   Instrument Review:   Calibration OK	Previous failures											
Peer comparison OK  Instrument Review: Calibration OK IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	-											
Instrument Review: Calibration OK	Any bias or trends											
Maintenance OK												
	Calibration OK											

## Assessment:

□ No further action required at this time test performance is acceptable.

□ Issue detected, complete full SEICAR.

Completed by:

The College of American Pathologists recommends that the result of this interlaboratory comparison not be used as a sole criterion for judging the performance of any individual clinical laboratory.

	CAP Number: 7196153-01 Kit# 1	Kit ID: 26431235
325 Waukegan Road, Northfield, Illinois 60093-2750 800-323-4040 • http://www.cap.org	Institution: Shady Grove Adventist Emergency Ctr Lab	Kit Mailed: 3/3/2014
Advancing Excellence	Attention: Cynthia Bowman-Gholston MT(ASCP) City / State: Germantown MD 20874-1221	Original Evaluation: 4/3/2014
	·	

EVALUATION ORIGINAL

AL2-A 2014 Alcohol/Ethylene Glycol/Volatiles

CMS Peformance Summary for Analytes Regulated Under the Clinical Laboratory Improvement Amendments of 1988

CLIA ID #: 21D1057352 Subspecialty : Toxicology											
	Proficiency Event 2013 2		Proficiency Event		Proficiency Event						
			2013 3		2014 1		Current Event Performance	Cumulative CLIA '88 Performance			
Regulated Analyte	Test Event	Score	%	Test Event	Score	%	Test Event	Score	%	Interpretation	Interpretation
Ethanol	AL2-B	5/5	100	AL2-C	5/5	100	AL2-A	5/5	100	Satisfactory	Successful
Toxicology		5/5	100		5/5	100		5/5	100	Satisfactory	Successful

The College of American Pathologists recommends that the result of this interlaboratory comparison not be used as a sole criterion for judging the performance of any individual clinical laboratory.